HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19.

AbstractBACKGROUND/AIMS:
The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers.
METHODS:
We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose.
RESULTS:
After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose.
CONCLUSION:
SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose.
AuthorsJi Yeun Kim, Ji-Soo Kwon, Hye Hee Cha, So Yun Lim, Seongman Bae, Sung-Han Kim
JournalThe Korean journal of internal medicine (Korean J Intern Med) Vol. 37 Issue 6 Pg. 1234-1240 (11 2022) ISSN: 2005-6648 [Electronic] Korea (South)
PMID36217813 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Viral Vaccines
Topics
  • Humans
  • BNT162 Vaccine
  • COVID-19 (prevention & control)
  • COVID-19 Vaccines
  • Immunity
  • Immunoglobulin G
  • SARS-CoV-2
  • Vaccination
  • Viral Vaccines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: